Apex Biotechnology (Taiwan) Performance
| 1733 Stock | TWD 28.55 0.60 2.06% |
The firm shows a Beta (market volatility) of 0.19, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Apex Biotechnology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Apex Biotechnology is expected to be smaller as well. At this point, Apex Biotechnology Corp has a negative expected return of -0.0664%. Please make sure to confirm Apex Biotechnology's coefficient of variation, jensen alpha, and the relationship between the mean deviation and standard deviation , to decide if Apex Biotechnology Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Apex Biotechnology Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Apex Biotechnology is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
| Begin Period Cash Flow | 786.9 M | |
| Total Cashflows From Investing Activities | -35 M | |
| Free Cash Flow | 153.7 M |
Apex |
Apex Biotechnology Relative Risk vs. Return Landscape
If you would invest 2,985 in Apex Biotechnology Corp on August 30, 2024 and sell it today you would lose (130.00) from holding Apex Biotechnology Corp or give up 4.36% of portfolio value over 90 days. Apex Biotechnology Corp is generating negative expected returns and assumes 1.0482% volatility on return distribution over the 90 days horizon. Simply put, 9% of stocks are less volatile than Apex, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Apex Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Apex Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Apex Biotechnology Corp, and traders can use it to determine the average amount a Apex Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0633
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 1733 |
Estimated Market Risk
| 1.05 actual daily | 9 91% of assets are more volatile |
Expected Return
| -0.07 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Apex Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Apex Biotechnology by adding Apex Biotechnology to a well-diversified portfolio.
Apex Biotechnology Fundamentals Growth
Apex Stock prices reflect investors' perceptions of the future prospects and financial health of Apex Biotechnology, and Apex Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Apex Stock performance.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0434 | |||
| Profit Margin | 0.1 % | |||
| Operating Margin | 0.08 % | |||
| Current Valuation | 2.45 B | |||
| Shares Outstanding | 99.95 M | |||
| Price To Earning | 31.02 X | |||
| Price To Book | 1.46 X | |||
| Price To Sales | 1.12 X | |||
| Revenue | 2.13 B | |||
| EBITDA | 293.14 M | |||
| Cash And Equivalents | 523.23 M | |||
| Cash Per Share | 5.25 X | |||
| Total Debt | 526.89 M | |||
| Debt To Equity | 31.40 % | |||
| Book Value Per Share | 17.73 X | |||
| Cash Flow From Operations | 179.87 M | |||
| Earnings Per Share | 2.17 X | |||
| Total Asset | 2.67 B | |||
| Retained Earnings | 617 M | |||
| Current Asset | 1.76 B | |||
| Current Liabilities | 638 M | |||
About Apex Biotechnology Performance
Evaluating Apex Biotechnology's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Apex Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Apex Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Apex Biotechnology Corp. engages in the research, development, manufacture, and sale of medical devices by using biosensor technology worldwide. Apex Biotechnology Corp. was founded in 1997 and is headquartered in Hsinchu, Taiwan. APEX BIOTECHNOLOGY operates under Biotechnology classification in Taiwan and is traded on Taiwan Stock Exchange.Things to note about Apex Biotechnology Corp performance evaluation
Checking the ongoing alerts about Apex Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Apex Biotechnology Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Apex Biotechnology generated a negative expected return over the last 90 days | |
| About 16.0% of the company shares are owned by insiders or employees |
- Analyzing Apex Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Apex Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Apex Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Apex Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Apex Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Apex Biotechnology's stock. These opinions can provide insight into Apex Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Apex Stock Analysis
When running Apex Biotechnology's price analysis, check to measure Apex Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apex Biotechnology is operating at the current time. Most of Apex Biotechnology's value examination focuses on studying past and present price action to predict the probability of Apex Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apex Biotechnology's price. Additionally, you may evaluate how the addition of Apex Biotechnology to your portfolios can decrease your overall portfolio volatility.